. 2023 Dec 5;97(12):e01105-23. doi: 10.1128/jvi.01105-23

TABLE 2.

Clinical characteristics of HCV+/HIV+ individuals (n = 20)

Parameter	Baseline	EOT	Follow-up
CD4 count (cells/uL)^c	603.5 (298–1,452)	696 (220–1,618)	625 (233–1,463)
CD8 count (cells/uL)^c	694 (255–2,218)	760.5 (242–2,817)	695 (192–2,223)
CD4/CD8 ratio^c	0.75 (0.3–2.1)	0.75 (0.2–1.9)	0.9 (0.3–1.7)
Liver stiffness (kPa)	7.7 (5.3–31.2)	NA	6.4 (3.7–29.9)^a^,d
ALT (U/L)^c	42 (17–128)	15.5 (8–70)^b^,d	15.5 (7–44)^b^,^d
AST (IU/L)^c	39 (21–136)	24 (11–45)^b^,^d	22.5 (10–48)^b^,^d
Albumin (g/dL)^c	39 (32–49)	41 (38–46)	42.5 (36–50)^b^,^d
Platelets (×10³/mm³)^c	192 (82–295)	190.5 (86–343)	178.5 (99–313)
Total bilirubin (ug/dL)^c	8.9 (3–47)	7.1 (4.7–48.2)	8.6 (3–26)

^{^a}

Wilcoxon test.

^{^b}

Friedman test.

^{^c}

Median (range).

^{^d}

Difference from baseline is significant (P value < 0.05).